Floatz logo

Deferasirox

Noncontiguous Stage II Marginal Zone Lymphoma

Wake Forest University Health SciencesSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Noncontiguous Stage II Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
Zofran
Fred Hutchinson Cancer Center
Phase 2B
Apolizumab
National Cancer Institute (NCI)
Phase 1CC
Palifermin
Martin, Paul
N/AD
LITHIUM, ELEMENTAL
Fred Hutchinson Cancer Center
N/AD
Plerixafor
Case Comprehensive Cancer Center
N/AD

Same molecule, other indications

Deferasirox is also rated in:

iron poisoningDormant
A
Indicative ·
82 / 100
View asset →
hemosiderosisDormant
A
Indicative ·
81 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →